Pseudotyped Viruses for Lyssavirus

Wang, Wenbo; Long, Caifeng; Wang, Lan; Wang, Youchun

doi:10.1007/978-981-99-0113-5_10

Cited by 2 publications

(2 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One way to circumvent these limitations is to use surrogate systems that recapitulate specific steps of the infection cycle, such as viral pseudotypes, in which the receptor-binding protein (RBP) of an enveloped virus of interest is incorporated into a viral vector. Pseudotyping has been applied to most families of enveloped RNA viruses and can faithfully reproduce key processes such as receptor usage, cellular tropism, viral entry routes, and antibody-mediated neutralization 12 .…”

Section: Introductionmentioning

confidence: 99%

Viral entry is a weak barrier to zoonosis

Dufloo,

Andreu-Moreno,

Valero-Rello

et al. 2024

Preprint

View full text Add to dashboard Cite

Recent advances in viral metagenomics have led to the discovery of many mammalian viruses, but experimental tests to determine whether they pose a threat to humans are largely lacking. A first step for a virus to cross the species barrier is to penetrate host cells. Here, we use gene synthesis and viral pseudotyping to experimentally test the ability of viral receptor-binding proteins (RBPs) from >100 enveloped RNA viruses to mediate entry into human cells. Analysis of thousands of RBP-cell pairs demonstrated such ability for most viruses, with significant variation among the 14 viral families studied. Comparison of RBP-mediated infectivity with cellular gene expression data showed that viral entry is often not limited by the presence of a receptor and revealed the contribution of additional host factors. Our results prove the weakness of interspecies barriers at the early stages of infection and identify molecular interactions that enable viral zoonosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Viral entry is a weak barrier to zoonosis

Dufloo,

Andreu-Moreno,

Valero-Rello

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…The laboratory use of pseudotyped virus particles has many advantages, particularly in the study of highly pathogenic viruses, as they can be handled in low-containment facilities, in tropism, drug screening, the screening and evaluation of monoclonal antibodies, vaccine evaluation and serosurveillance studies. 21,22 Neutralization assays are useful tools to study antibody responses after natural exposure to viruses, or responses elicited by vaccination. These assays normally require the application of wild-type viruses, which can be limiting if the virus in use is highly pathogenic in humans.…”

Section: Introductionmentioning

confidence: 99%

 A validate and standardized pseudotyped microneutralization assay as a safe and powerful tool to measure LASSA neutralising antibodies for vaccine development and comparison

Antonelli,

Forconi,

Molesti

et al. 2024

F1000Res

View full text Add to dashboard Cite

Background Over the past few decades, WHO has made massive efforts to promote the development of a vaccine against Lassa virus (LASV), one of the top ten priority pathogens for research and development under the WHO R&D Blueprint for Emerging Infections. To date, several vaccines are at different stages of development. In this scenario, a validated and standardised assay to measure LSV neutralising antibodies is urgently needed for vaccine development and comparison. Methods The neutralisation assay remains the gold standard for determining antibody efficacy. Here we have proposed a safe and validated pseudotyped neutralisation assay for LASV, taking advantage of the development of the first WHO International Standard and Reference Panel for Anti-Lassa Fever (NIBSC code 21/332). Results and Conclusions The proposed results demonstrate that the pseudotyped luciferase neutralisation assay is a specific serological test for the measurement of LASV neutralising antibodies without cross-reacting with standard sera specific for heterologous viral infections. In addition, the assay is accurate, precise, and linear according to criteria and statistical analyses defined and accepted by international guidelines.

show abstract

Pseudotyped Viruses for Lyssavirus

Cited by 2 publications

References 92 publications

Viral entry is a weak barrier to zoonosis

Viral entry is a weak barrier to zoonosis

A validate and standardized pseudotyped microneutralization assay as a safe and powerful tool to measure LASSA neutralising antibodies for vaccine development and comparison

Contact Info

Product

Resources

About